^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Ovarian Serous Adenocarcinoma
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

    Excerpt:
    ...- For enrollment to expansion cohort 2, patients must have high-grade serous ovarian or fallopian tube cancer and documentation of BRCA1 or BRCA2 mutation by a CLIA certified lab....
    Trial ID:
    NCT03057145
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase 1 Combination Study of the CHK1 inhibitor prexasertib, and the PARP inhibitor olaparib, in high-grade serous ovarian cancer and other solid tumors

    Published date:
    06/15/2021
    Excerpt:
    Four of 18 pts with BRCA1-mutant, PARP inhibitor-resistant, high-grade serous ovarian cancer (HGSOC) achieved PRs….Prexasertib combined with olaparib has preliminary clinical activity in pts with BRCA-mutant HGSOC who have previously progressed on a PARP inhibitor.
    DOI:
    10.1158/1078-0432.CCR-21-1279